Clinical Trial Setback and Context

Bristol Myers Squibb (NYSE: BMY) recently faced a significant R&D setback. In mid-November 2025, BMY and partner Johnson & Johnson halted a late-stage trial of their experimental blood thinner milvexian after an independent analysis indicated the drug was unlikely to meet its primary efficacy goal (^[1]). The trial, targeting prevention of repeat cardiac events in acute coronary syndrome patients, showed little chance of benefit when milvexian was added to standard therapy (aspirin or clopidogrel) (^[1]). On the news, BMY’s shares dropped about 5% in premarket trading (^[1]). This “trial disappointment” highlights the pipeline risks facing the company and raises questions about its growth trajectory. In the wake of this development, investors are examining BMY’s fundamentals – from its dividend policy and leverage to valuation and risk factors – to gauge what it means for their portfolios.

Dividend Policy, History & Yield

BMY has a long track record of paying dividends and modestly growing the payout. The company’s Board approves dividends quarterly, and cash dividends declared per share have increased from $2.01 in 2021 to $2.19 in 2022 and $2.31 in 2023 (^[2]). This roughly 5–9% annual growth in recent years underscores BMY’s commitment to returning cash to shareholders even during major acquisitions and patent expiration headwinds. The latest quarterly dividend was $0.62 per share, putting the forward annualized dividend around $2.48. With BMY’s stock price under pressure – recently trading near multi-year lows in the mid-$40s – the dividend yield has risen to roughly 5% (^[3]), well above the S&P 500 average. This high yield partly reflects a depressed share price, as investors have grown cautious about BMY’s growth prospects.

Dividend coverage appears solid for now. In 2023, BMY’s operations generated $13.9 billion in cash, while the company paid out about $4.7 billion in dividends (and also repurchased ~$5.2 billion in stock) (^[2]) (^[2]). Even after these shareholder returns and capital investments, BMY reduced its net debt by nearly $3 billion that year (^[2]). This indicates the dividend was well-covered by free cash flow, with room to spare. On an earnings basis, the dividend payout ratio is reasonable – about 30% of 2023 adjusted earnings (non-GAAP) or ~60% of GAAP earnings (^[2]) (^[2]). However, looking ahead, management has cautioned that future capital allocation will depend on business performance and investment needs. In fact, BMY explicitly notes that large strategic acquisitions (and the debt used to fund them) could “reduce [its] financial flexibility to continue… [to] declare future dividends.” (^[2]) For now, the dividend looks secure and continues to grow, but investors should monitor BMY’s cash flows as the company navigates its patent cliff (more below).

Leverage, Debt Maturities & Coverage

BMY’s balance sheet carries substantial debt due to recent acquisitions (such as Celgene in 2019 and others in 2022–2024). As of year-end 2023, the company had $39.5 billion in total debt (including $36.7B long-term) (^[2]) (^[2]). Net debt stood around $27 billion after accounting for cash holdings (^[2]). Importantly, BMY has managed its debt maturity profile prudently. Over the next five years, annual debt maturities are moderate and spread out – about $2.9 billion due in 2024, $1.9B in 2025, $2.0B in 2026, $2.0B in 2027, and $1.5B in 2028 (^[2]). This laddered schedule should help BMY refinance or repay obligations without undue strain on any single year’s cash flow.

The company’s investment-grade credit ratings provide further reassurance. Standard & Poor’s rates BMY’s long-term debt A (stable), a notch lower than its previous A+ rating, after the announcement of two sizeable acquisitions in late 2023 (Karuna Therapeutics and RayzeBio) (^[2]). BMY took on bridge financing to fund these deals, but management intends to refinance with longer-term securities and then focus on deleveraging over time (^[2]). Maintaining an “investment grade credit rating, growing the dividend and reducing debt” remain stated financial priorities for BMY (^[2]).

Interest coverage – a measure of how easily operating earnings cover interest expense – is adequate, though not best-in-class among large pharma peers. In the third quarter of 2025, BMY’s interest coverage was roughly 7.6×, meaning earnings were over seven times its interest obligations (^[4]). This is a comfortable cushion above typical lender requirements, and well above the 5× threshold value investors like Benjamin Graham encouraged (^[4]). However, BMY’s debt-heavy balance sheet (a legacy of its aggressive M&A strategy) makes its coverage ratio lag many competitors – the industry median coverage is about 12×, whereas BMY’s figure (on a trailing basis) is around 5–7×, placing it in the weaker one-third of its drug industry peer group (^[4]). The upshot: BMY can readily service its debt interest for now, but it has less headroom than more conservatively financed peers. Continued earnings pressure or rising interest rates could tighten that coverage, so investors should watch BMY’s leverage in the coming years, especially as it digests new acquisitions.

Valuation and Comparative Metrics

BMY’s stock currently trades at depressed valuation multiples relative to both the broader market and its big-pharma peers. The combination of share price declines and resilient (albeit plateauing) earnings has left BMY with a single-digit price/earnings ratio on forward earnings. In fact, after updating guidance, management expects 2025 full-year earnings of $6.35–$6.65 per share (^[5]) (on an adjusted basis), which implies a forward P/E well under 8× at the recent stock price in the mid-$40s. This is a steep discount to the S&P 500 (currently ~19× forward earnings) and even below other pharma names facing their own challenges. For instance, Pfizer and AbbVie also sport low multiples and elevated yields amid patent and product pressures, but BMY is among the cheapest. Some value-focused investors have taken notice: healthcare stocks broadly are trading near a “30-year high” discount to the market, and “select stocks like Merck and Bristol Myers Squibb are trading at deep discounts” that are drawing bargain hunters (^[6]) (^[6]). BMY’s dividend yield above 5% further signals its value-stock status in today’s market (^[3]).

That said, low valuation alone doesn’t guarantee upside. There is a debate whether BMY is a value opportunity or a potential “value trap.” The bear case is that BMY’s earnings are at risk of shrinking in the near term (more on this in Risks below), so a low P/E might simply reflect a contracting “E.” In early 2025, BMY warned of a sharper revenue and profit decline than analysts expected due to patent expirations, initially forecasting 2025 sales to fall to ~$45.5B (versus ~$46–47B in prior years) and acknowledging EPS would likely come in below consensus (^[7]) (^[7]). While the company has since slightly improved its outlook (helped by cost cuts and better-than-feared drug erosion), the growth picture remains challenged. In sum, BMY’s valuation is cheap for a reason – investors are demanding a low price multiple to compensate for the uncertainty ahead. A re-rating to higher multiples would require renewed confidence that BMY can stabilize and grow its earnings in the post-patent-cliff era. Until then, the stock may remain in the penalty box, even though income-oriented investors are being paid handsomely (via the dividend) to wait.

Key Risks, Red Flags and Challenges

BMY faces several notable risks and potential red flags that could impact shareholders going forward:

– Patent Expirations (Loss of Exclusivity) – The biggest known risk is the ongoing loss of exclusivity (LOE) for several of BMY’s blockbuster drugs. The company is currently in what management calls a “transition period” due to major patent cliffs (^[8]). Notably, multiple myeloma drug Revlimid – inherited from Celgene – has seen sales plunge as generics enter the market. In Q3 2025, Revlimid sales dropped 59% year-over-year (^[9]), and BMY expects Revlimid revenue to dwindle to around $3B in 2025 (down from a peak of ~$12B a few years ago) (^[5]) (^[5]). Other formerly high-margin drugs are in decline too: Pomalyst (another myeloma therapy) and Abraxane (a cancer drug) are facing generic competition or usage declines (^[9]). Even BMY’s top-selling anticoagulant Eliquis (co-marketed with Pfizer) will lose patent protection later this decade (2026–2028 timeframe), posing a future revenue cliff. The patent expirations are a certainty, and they are already driving a drop in BMY’s overall revenues (^[7]). This is a structural challenge for the company – essentially, BMY must replace billions in high-margin sales just to tread water.

– Pipeline and R&D Setbacks – Replenishing the lost revenue depends on BMY’s drug pipeline delivering new successes. Here, the recent trial disappointment serves as a cautionary tale. The halted milvexian trial removed one potential growth driver in the cardiovascular space (though two other trials of milvexian in different indications continue) (^[1]). Earlier in 2025, BMY also disclosed that a Phase 3 trial of its new schizophrenia drug Cobenfy failed to show benefit as an add-on therapy (^[8]). Cobenfy (also known as KarXT) had just been FDA-approved for schizophrenia and was touted as a key future growth asset for BMY, so the setback in an expansion trial was a blow to its “blockbuster” ambitions (^[8]). These incidents highlight the execution risk in BMY’s R&D pipeline – not every experimental indication will pan out. While BMY does have promising programs (in oncology, cardiology, immunology, and now neuroscience), investors should expect some volatility. Pipeline failures can hurt sentiment (as we saw with the 5% stock drop on the milvexian news) and delay the company’s turnaround. In short, new drugs must succeed commercially to fill the patent gap, and there’s no guarantee all will go as planned.

– Acquisition Integration & Leverage – BMY’s response to the patent cliff has been aggressive business development: the company has spent tens of billions on acquisitions and partnerships to bolt on new assets. From the $74B Celgene takeover in 2019 to more recent deals like MyoKardia (2020), Turning Point (2022), Mirati (2024), and planned acquisitions of Karuna (a neuroscience firm) and RayzeBio (oncology) in 2024–2025, BMY is actively “buying” pipeline (^[2]) (^[2]). This strategy brings opportunity but also risk. Integrating new companies and R&D programs can strain management and finances. The debt load has risen with each deal (as noted, ~$39B debt outstanding), and credit rating agencies reacted – S&P downgraded BMY one notch to ‘A’ after the latest acquisition announcements (^[2]). BMY insists it remains committed to deleveraging, but further big acquisitions could constrain its ability to invest or even to keep growing the dividend (^[2]). There’s also execution risk: BMY needs these acquisitions to pay off. For example, Karuna’s KarXT drug (which BMY will own via the Karuna deal) could be a game-changer in psychiatry – but its commercial success and expansion into broader use are not assured (as shown by the adjunct therapy trial failure). If expensive acquisitions don’t generate the expected cash flows, BMY could be left with a heavy debt burden and underperforming assets. Investors should be alert to how well BMY integrates new pipelines and whether it can realize synergies without overextending financially.

– Regulatory and Policy Overhang – Like all big pharma companies, BMY operates under evolving healthcare policies and political scrutiny on drug pricing. The U.S. (BMY’s largest market) has been pursuing measures to curb drug prices and adjust Medicare reimbursement, which could pressure revenue. Reuters noted that heading into 2025, the sector faced headwinds from policies to lower drug prices, potential pharmaceutical tariffs, and reduced healthcare funding (^[6]). BMY’s management has flagged concern over government pricing rules – the company is “actively engaging with the government over healthcare policy changes.” (^[9]) While broad industry reforms impact all players, BMY’s heavy reliance on a few high-priced, specialty drugs (e.g. Opdivo, Eliquis) means any pricing cuts or negotiation mandates on those could hit its bottom line disproportionately. Ongoing regulatory uncertainties are a risk factor that investors should keep in mind, even if it’s hard to quantify in advance.

– Other Red Flags – BMY’s overall business is in a transition, and a few additional items are worth monitoring. First, the company underwent a leadership change in 2023, with longtime CEO Giovanni Caforio stepping down and Christopher Boerner (formerly chief commercialization officer) taking the helm (^[9]). A new CEO often brings strategic shifts – Boerner has doubled down on partnerships and deals (^[9]). Investors will want to see if this strategy delivers results, or if it simply adds risk. Second, BMY’s share price weakness itself can be a red flag: the stock’s underperformance (despite earnings beats in recent quarters) suggests the market is skeptical of BMY’s long-term growth. A high dividend yield is appealing, but as analysts caution, a very high yield can signal market expectations of trouble ahead (^[6]). In BMY’s case, the ~5% yield has risen in part because the stock slid over the past year, so it’s important to discern if this is an attractive entry point or a warning sign. Finally, legal and pipeline setbacks (common in pharma) should be watched – for example, any surprise negative data from other late-stage trials, or adverse litigation outcomes, could quickly become the next red flag.

Open Questions and Outlook for Investors

Given these factors, what should investors consider for their portfolios? A few open questions will determine how BMY fares in the coming years:

– Can New Products Offset the Patent Cliff? BMY’s future hinges on its “next generation” portfolio. There have been some positives: the core immunotherapy Opdivo is still growing (sales up 7% in Q3 2025) (^[9]), Eliquis continues to expand usage (25% sales growth in Q3) (^[9]), and new launches like heart drug Camzyos (for cardiomyopathy) and cell therapies are contributing to an 18% rise in BMY’s so-called “growth portfolio” revenue (^[9]). The approval of Cobenfy (KarXT) for schizophrenia was a notable win in 2024, giving BMY a foothold in neuroscience (^[7]) (^[10]). However, the big question is whether these and upcoming launches (plus pipeline candidates in oncology, immunology, cardiovascular, etc.) can ramp up fast enough to replace the billions lost from Revlimid, Pomalyst, and other aging drugs (^[7]). Investors should watch sales trends of key new products (e.g., Camzyos, Cobenfy, cell therapies like Abecma and Breyanzi, upcoming immunotherapies, etc.) and any clinical milestones. If BMY’s new drugs underwhelm, the company may face a prolonged revenue and earnings dip, challenging the stock’s recovery. On the other hand, successful launches could restore growth by the late 2020s – a bullish scenario not fully reflected in today’s low valuation.

– Will BMY’s Pipeline Deliver or Stumble? The halted milvexian trial and Cobenfy’s adjunct failure underscore that R&D is unpredictable (^[1]) (^[8]). BMY has several pivotal trials reading out in the next 1–2 years (including the remaining Phase III studies for milvexian in atrial fibrillation and stroke prevention, expected in 2026 (^[1])). The outcomes of these trials are open questions that could swing the stock. Additionally, integration of acquired pipelines (Karuna’s neuro assets, Mirati’s oncology drugs, etc.) introduces uncertainty – will those drug candidates meet expectations in clinical testing and regulatory approval? BMY’s ability to consistently bring new blockbusters to market is unproven since the Celgene acquisition; thus, R&D execution is a key question. Investors may want to monitor R&D updates closely, as any surprise breakthroughs or disappointments will likely be reflected quickly in BMY’s share price.

– How Will Management Balance Investing for Growth vs. Shareholder Returns? With limited growth in the near term, BMY is in a balancing act. The company is expanding a cost-cutting program by an extra $2 billion through 2027 to streamline operations (^[7]), which should support earnings during the lean period. At the same time, it continues to invest in R&D and consider bolt-on acquisitions to bolster the pipeline. An open question is whether management can reignite growth without compromising financial discipline. For example, will BMY keep raising its dividend annually (as it has for many years) if earnings temporarily dip? Or could we see a pause in dividend growth to conserve cash? BMY thus far emphasizes its commitment to the dividend, but as noted, it has also acknowledged that heavy deal-making could limit future increases (^[2]). Additionally, the pace of share buybacks (BMY has been repurchasing shares actively) might slow if cash is needed elsewhere. The trajectory of debt is another aspect – BMY’s net debt actually fell in 2023 thanks to strong cash flow (^[2]), but pending acquisitions will reverse some of that progress. Investors will be looking for management to articulate a clear capital allocation strategy: how much goes into pipeline investments vs. rewarding shareholders. Striking the right balance is crucial for rebuilding market confidence.

– Is the Stock Positioned for Recovery or Further Weakness? Finally, shareholders must ask if BMY’s risk/reward profile is attractive now. The stock’s underperformance in 2025, despite generally better-than-expected quarterly results (^[9]) (^[5]), suggests skepticism runs high. If one believes “the worst may be priced in” for BMY and the healthcare sector (^[6]), then the current deep discount and 5% yield could be a great long-term entry point – essentially getting a blue-chip pharma franchise at a bargain valuation. The favorable view is that BMY’s diversified portfolio (oncology, cardiovascular, immunology, neuroscience) and big pipeline shots on goal increase the odds that something will go right, eventually enabling the company to emerge from the patent trough. In that case, patient investors could see significant upside as earnings stabilize and the P/E multiple normalizes upward. On the other hand, if BMY fails to execute – if new drugs don’t deliver and earnings keep eroding – the stock could stagnate or fall further, and that juicy dividend might come under pressure in a few years. This is the crux of BMY as an investment right now: it’s a classic high-yield, low-multiple stock where future outcomes are uncertain. Bulls see a misunderstood value play, while bears see a company in decline.

Bottom Line: The recent trial disappointment with milvexian is a reminder of the challenges BMY faces in revitalizing growth. For investors, BMY offers a solid dividend and stable near-term cash flows, but also a set of open questions about its pipeline and strategic direction. It can still serve as a defensive, income-generating holding in a portfolio – management’s cost cuts and the breadth of BMY’s portfolio provide some cushion against downside scenarios. However, meaningful upside likely hinges on clear signs that BMY can navigate the patent cliff by launching successful new drugs. Until more answers emerge on that front, investors should approach BMY with a balanced perspective: appreciate the reliable income and strong past execution, but stay vigilant about the risks and be ready to adjust if the company’s turnaround story falters. The next few years will be pivotal in determining whether this pharma giant’s stock remains a high-yield value play or returns to a growth footing, rewarding those who stayed the course.

Sources: The analysis above is grounded in information from Bristol Myers Squibb’s SEC filings and investor communications, as well as credible financial media. Key references include the company’s 2023 annual report (10-K) for financial and dividend data (^[2]) (^[2]), recent Reuters reports on BMY’s earnings and drug trials (^[9]) (^[1]), and industry commentary on the pharma sector’s challenges (^[6]). These sources provide a factual basis for the discussion of BMY’s dividend coverage, debt levels, valuation multiples, and the impact of events like the milvexian trial halt and patent expirations on the company’s outlook.

Sources

1. https://reuters.com/business/healthcare-pharmaceuticals/bristol-myers-jj-halt-heart-drug-trial-after-interim-review-2025-11-14/
2. https://sec.gov/Archives/edgar/data/14272/000001427224000044/bmy-20231231.htm
3. https://fintel.io/sd/us/bmy
4. https://gurufocus.com/term/interest_coverage/BMY
5. https://reuters.com/business/healthcare-pharmaceuticals/bristol-myers-posts-better-than-expected-second-quarter-results-strength-top-2025-07-31/
6. https://reuters.com/business/healthcare-pharmaceuticals/struggling-us-healthcare-stocks-endure-rough-2025-draw-some-bargain-hunters-2025-08-07/
7. https://reuters.com/business/healthcare-pharmaceuticals/bristol-sees-sharper-2025-revenue-drop-after-better-than-forecast-q4-2025-02-06/
8. https://fiercepharma.com/pharma/bristol-myers-schizophrenia-drug-cobenfy-stumbles-adjunctive-treatment-denting-blockbuster
9. https://reuters.com/business/healthcare-pharmaceuticals/bristol-myers-beats-quarterly-revenue-estimates-strong-opdivo-sales-2025-10-30/
10. https://fiercepharma.com/pharma/bmss-newly-approved-schizophrenia-drug-cobenfy-what-long-strange-trip-its-been

For informational purposes only; not investment advice.